Quantcast
Last updated on April 24, 2014 at 11:28 EDT

Latest Lupin Pharmaceuticals Inc. Stories

2010-01-28 11:16:00

BALTIMORE, Jan. 28 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg. Commercial shipments of the product will commence shortly. Lupin's Perindopril Erbumine tablets are AB-rated to ACEON®* tablets indicated for the treatment of patients with essential hypertension and can be used with conventional treatment for...

2010-01-21 09:27:00

BALTIMORE, Jan. 21 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received tentative approval from the US Food and Drug Administration (US FDA) for its Memantine Hydrochloride tablets, 5mg and 10mg. Lupin's Memantine HCl tablets are AB-rated to Namenda® tablets indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Namenda had annual sales of approximately $1.1 billion for the twelve months ended September...

2010-01-20 10:09:00

MUMBAI, India, Jan. 20 /PRNewswire/ -- Pharma major, Lupin Ltd announced today that it has received official communication from the US FDA on the satisfactory resolution of the Warning Letter issued earlier to its Mandideep site. The company had received a Warning letter for its Mandideep site in May 2009. In the ensuing seven months, the company made significant enhancements and took appropriate corrective actions. The facility was re-inspected in November 2009 and the company was able to...

2009-09-10 15:05:00

ARDEE, Ireland, Sept. 10 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that one of its subsidiaries has filed two lawsuits against Lupin Limited and its wholly owned subsidiary Lupin Pharmaceuticals, Inc. (collectively "Lupin") in the District Court for the District of Delaware for infringement of Warner Chilcott's U.S. Patent Nos. 5,552,394 (the "'394 Patent") and 6,667,050 (the "'050 Patent"), which cover oral contraceptives LOESTRIN 24 FE and FEMCON FE,...

2009-01-16 09:36:00

BALTIMORE, Jan. 16 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval for the Company's Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750mg and 1000mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have commenced. Lupin's Levetiracetam tablets are the AB-rated generic equivalent of UCB Pharmaceuticals' Keppra(R) tablets, indicated as adjunctive therapy in the...

2008-09-16 18:00:34

BALTIMORE, Sept. 16 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it received the "2008 2nd Quarter recipient of the Award of Excellence" from Wal-Mart Stores, Inc. Commenting on the award, Vinita Gupta, President and Managing Director of Lupin Pharmaceuticals, Inc. said, "Receiving this award from the world's largest retailer validates everything that Lupin stands for: strictest compliance to regulations, absolute dedication to product quality and total commitment...

2008-08-19 15:01:22

MUMBAI, India and BALTIMORE, Aug. 19 /PRNewswire/ -- Lupin Ltd. announced today that the Company has entered into a multi-year promotion and marketing agreement for the AeroChamber Plus(R) line of products with Forest Laboratories, Inc. Under the terms of the agreement, Lupin Pharmaceuticals, Inc., USA, will use its 50 person sales force to promote the product to pediatricians. AeroChamber Plus(R) is a Valved Holding Chamber (VHC) device that is used with metered dose inhalers to improve...

2008-07-31 12:01:05

BALTIMORE, July 31 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval for the Company's Abbreviated New Drug Application (ANDA) for Divalproex Sodium Delayed-Release Tablets, 125 mg, 250 mg and 500 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have already commenced. Lupin's Divalproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories' Depakote(R)...

2008-06-24 02:29:21

BALTIMORE, June 23 /PRNewswire/ -- Lupin Pharmaceuticals, a subsidiary of Lupin Ltd., announced today that the Company has entered into a promotion agreement for Suprax(R) 400 mg Tablets with ASCEND Therapeutics, Inc. Under the terms of the alliance, ASCEND Therapeutics will initiate promotion of the product in the U.S. in the month of June 2008. ASCEND has a 50-person Women's Health sales force which will detail the product primarily to Obstetricians and Gynecologists (OB/GYNs). Lupin...

2008-06-16 12:01:04

BALTIMORE, June 16 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Escitalopram Oxalate Tablets 10 mg and 20 mg from the U.S. Food and Drug Administration (USFDA). Lupin's Escitalopram tablets are the AB-rated generic equivalent of Forest Laboratories' Lexapro(R) tablets, indicated for the treatment of major depressive disorder. The brand product had annual sales of...